Pathological Gambling Clinical Trial
Verified date | December 2011 |
Source | Lindner Center of HOPE |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
The purpose of this research study is to evaluate the efficacy (effectiveness) and safety of olanzapine in treating pathological gambling.
Status | Completed |
Enrollment | 42 |
Est. completion date | March 2009 |
Est. primary completion date | March 2009 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: 1. Male and female outpatients aged 18- 75 years of age. 2. Patients will have problematic gambling behavior of at least 6 months duration that meets the DSM-IV definition of pathological gambling and a South Oaks Gambling Screen Score greater than 5. 3. All patients will have a complete medical and psychiatric history, physical examination, laboratories, and ECG before study entry. 4. Baseline laboratory values and ECG must be normal, or abnormalities must be clinically insignificant. 5. Patients will not have received any psychotropic medication for at least one week prior to the first study visit. Exclusion Criteria: 1. Patients who have any significant and/or unstable gastrointestinal, neurological, endocrine, cardiovascular, pulmonary, renal, hepatic, immunological or hematological disease; organic brain disease; or cancer as determined by history, physical, ECG, and laboratory examination. 2. Patients who are pregnant, intending to become pregnant, nursing, at risk for pregnancy, or not practicing medically acceptable birth control. (A blood pregnancy test will be performed at the screening visit). 3. Patients who have ever had psychotic symptoms, who have ever met DSM-IV criteria for a manic episode (i.e., have bipolar I disorder), or who have met criteria for DSM-IV psychoactive substance dependence in the past 1 month. 4. Patients who meet DSM-IV criteria for antisocial or borderline personality disorder. 5. Patients who use any medications which, in the judgment of the investigator, might have psychotropic effects, or interact unfavorably with olanzapine. For example, patients taking diet pills or stimulants will not be enrolled. 6. Patients who have taken any psychiatric medication within 7 days prior to the screening assessment. 7. Patients who have a history of hypersensitivity to olanzapine. 8. Patients who display clinically significant suicidal ideation. 9. Patients who have recently (within the past 3 months) begun any type of non-pharmacologic treatment for pathological gambling (including psychotherapy, behavior therapy, group therapy, or family therapy). This does not exclude participation in support groups (e.g., Gamblers Anonymous.) Patients who have been involved in long-standing psychological therapies (e.g., psychotherapy for at least the last 3 months) will be permitted to continue in that therapy provided that no new therapeutic technique or increase in frequency of psychotherapy occurs concurrent with the study. 10. Patients who exhibit or suggest that they may display behavior that will not be conducive to the study procedures. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | University of Cincinnati Medical Center | Cincinnati | Ohio |
Lead Sponsor | Collaborator |
---|---|
Lindner Center of HOPE | Eli Lilly and Company, University of Cincinnati |
United States,
McElroy SL, Nelson EB, Welge JA, Kaehler L, Keck PE Jr. Olanzapine in the treatment of pathological gambling: a negative randomized placebo-controlled trial. J Clin Psychiatry. 2008 Mar;69(3):433-40. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pathological Gambling Adaptation of the Yale-Brown Obsessive Compulsive Scale (PG-YBOCS) | per protocol | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02590211 -
Poker, Skills and Associated Problems
|
N/A | |
Completed |
NCT02203786 -
D1 and D2 Dopamine Receptors in Gambling and Amphetamine Reinforcement
|
Phase 2 | |
Completed |
NCT05051085 -
Feasibility of the Internet-delivered Treatment "SpilleFri" for Patients With Pathological Gambling
|
N/A | |
Completed |
NCT01215357 -
Clinical Study to Determine if Ecopipam Can Reduce Urges to Gamble
|
Phase 2 | |
Terminated |
NCT00245583 -
Topiramate in the Treatment of Pathological Gambling
|
Phase 3 | |
Completed |
NCT04842461 -
Mental Health, Addictions and Biomarkers in High Athletes Performance
|
||
Not yet recruiting |
NCT03280966 -
Effects of Intranasal Naloxone on Gambling Urges in Gambling Disorder
|
Phase 2 | |
Active, not recruiting |
NCT01743092 -
Testing Resources: Manual and Webinar Guided Treatment vs. Manual Guided Treatment
|
N/A | |
Active, not recruiting |
NCT01528982 -
Susceptibility to Pathological Gambling
|
N/A | |
Terminated |
NCT00211822 -
Functional Magnetic Resonance Imaging (fMRI) Studies in Pathological Gambling (PG) and Obsessive-Compulsive Disorder (OCD)
|
N/A | |
Completed |
NCT01381250 -
Effects of Internet-based Treatment of Pathological Gambling
|
N/A | |
Completed |
NCT05506384 -
Treatment Study for Problematic Gaming and Gambling
|
N/A | |
Enrolling by invitation |
NCT03464838 -
Effects of Transcranial Direct Current Stimulation (tDCS) in Gambling Disorder
|
N/A | |
Terminated |
NCT01560351 -
Repeated Low-frequency Transcranial Magnetic Stimulation Reduces Cue-induced Craving: a Randomized, Prospective, Double-blind, Sham-controlled, Cross-over Study
|
N/A | |
Completed |
NCT00580567 -
Impulsivity in Pathological Gambling
|
N/A | |
Completed |
NCT02240485 -
Integrative Couple Treatment for Pathological Gambling
|
N/A | |
Withdrawn |
NCT01340274 -
Community Reinforcement Approach and Family Training (CRAFT) for Problem Gambling
|
Phase 2 | |
Recruiting |
NCT02491996 -
The Efficacy of Therapy Focused on Desire-satisfaction for Disordered Gamblers
|
N/A | |
Recruiting |
NCT01154712 -
Deep Low-Frequency Repetitive Transcranial Magnetic Stimulation for Cessation of Pathological Gambling
|
Phase 1 | |
Completed |
NCT01843699 -
Topiramate Trial for Pathological Gamblers
|
Phase 2 |